NRx Pharmaceuticals Has Signed A Development Contract To Manufacture A Presentation Of Ketamine Suitable For Intravenous Administration Under Current FDA Manufacturing Regulations
Portfolio Pulse from Benzinga Newsdesk
NRx Pharmaceuticals has signed a contract to develop a version of Ketamine suitable for intravenous administration under current FDA manufacturing regulations. Existing supplies of Ketamine are not labeled for treatment of depression and suicidality and often do not meet modern manufacturing requirements for single-dose injectable medications.
October 31, 2023 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NRx Pharmaceuticals' new contract to develop FDA-compliant Ketamine could potentially open up a new market for the company. However, the development process may require significant resources and time.
The news of NRx Pharmaceuticals signing a contract to develop a version of Ketamine that is suitable for intravenous administration under current FDA manufacturing regulations is directly relevant to the company. This could potentially open up a new market for the company, which could positively impact its stock price. However, the development process may require significant resources and time, which could have a negative impact in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100